HCWB Logo

HCW Biologics Inc. (HCWB) 

NASDAQ$0.34
Market Cap
$15.15M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
616 of 924
Rank in Industry
354 of 527

HCWB Insider Trading Activity

HCWB Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$00
Sells
$00

Related Transactions

No records found

About HCW Biologics Inc.

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Insider Activity of HCW Biologics Inc.

Over the last 12 months, insiders at HCW Biologics Inc. have bought $0 and sold $0 worth of HCW Biologics Inc. stock.

On average, over the past 5 years, insiders at HCW Biologics Inc. have bought $2.97M and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,800 shares for transaction amount of $3,741 was made by Wong Hing C (Chief Executive Officer) on 2023‑09‑14.

List of Insider Buy and Sell Transactions, HCW Biologics Inc.

2023-09-14PurchaseWong Hing CChief Executive Officer
1,800
0.0049%
$2.08$3,741-46.48%
2023-09-14PurchaseWiner Gary Mdirector
1,041
0.0028%
$2.05$2,139-46.48%
2023-09-13PurchaseByam RebeccaChief Financial Officer
5,000
0.0144%
$2.10$10,490-43.32%
2023-09-13PurchaseWiner Gary Mdirector
546
0.0015%
$2.05$1,117-43.32%
2023-09-12PurchaseByam RebeccaChief Financial Officer
5,000
0.0143%
$2.09$10,442-43.35%
2023-09-12PurchaseWiner Gary Mdirector
500
0.0014%
$2.05$1,025-43.35%
2023-09-11PurchaseByam RebeccaChief Financial Officer
5,000
0.0145%
$2.05$10,273-41.62%
2023-09-11PurchaseWiner Gary Mdirector
99
0.0003%
$2.05$203-41.62%
2023-09-08PurchaseByam RebeccaChief Financial Officer
5,000
0.0137%
$2.02$10,111-43.90%
2023-09-08PurchaseWiner Gary Mdirector
1
<0.0001%
$1.90$2-43.90%
2023-09-07PurchaseByam RebeccaChief Financial Officer
5,000
0.0139%
$1.95$9,742-41.03%
2023-09-07PurchaseWiner Gary Mdirector
63
0.0002%
$1.95$123-41.03%
2023-09-06PurchaseByam RebeccaChief Financial Officer
5,000
0.0144%
$1.95$9,749-39.15%
2023-09-05PurchaseWiner Gary Mdirector
400
0.0011%
$1.75$700-41.03%
2023-06-09PurchaseByam RebeccaChief Financial Officer
20,000
0.057%
$2.06$41,286-20.79%
2023-06-08PurchaseByam RebeccaChief Financial Officer
4,696
0.0135%
$2.21$10,388-25.58%
2023-06-08PurchaseFlowers LeeSVP of Business Development
10,000
0.028%
$2.16$21,574-25.58%
2023-06-07PurchaseByam RebeccaChief Financial Officer
20,000
0.0542%
$2.03$40,632-23.37%
2023-06-06PurchaseByam RebeccaChief Financial Officer
19,062
0.0524%
$1.82$34,779-13.51%
2023-06-05PurchaseByam RebeccaChief Financial Officer
20,000
0.054%
$1.67$33,344-6.98%
Total: 57

Insider Historical Profitability

<0.0001%
Wong Hing CChief Executive Officer
15314868
34.3807%
$5.21M140<0.0001%
Byam RebeccaChief Financial Officer
573946
1.2885%
$195,141.64220<0.0001%
GARRETT SCOTT Tdirector
125000
0.2806%
$42,500.0010<0.0001%
Flowers LeeSVP of Business Development
111308
0.2499%
$37,844.7250<0.0001%
Rhode PeterSee Remarks
46785
0.105%
$15,906.9010<0.0001%
Jiao Jin-anVP of Development
30571
0.0686%
$10,394.1410<0.0001%
Winer Gary Mdirector
17000
0.0382%
$5,780.00110<0.0001%
Greene Rick S.
8411
0.0189%
$2,859.7420<0.0001%

Historical Insider Profitability vs. Competitors

HCW Biologics Inc.
(HCWB)
$8,900,811
57
-24.79%
$15.15M
$85,897,100
36
2.47%
$17.01M
$217,684
34
1.61%
$17.89M
$4,368,362
28
-22.35%
$14.54M
$550,893
22
-22.12%
$15M
$555,628
21
43.52%
$17.92M
$206,127
21
-29.00%
$16.71M
$2,553,853
17
16.69%
$15.38M
$37,194,483
17
-51.30%
$15.85M
$122,973
15
-26.96%
$14.53M
$389,864
11
12.52%
$15.03M
$38,247,728
10
-10.97%
$13.84M
$36,538,405
10
-21.99%
$14.11M
$70,584,874
10
3.97%
$15.33M
$189,648
9
-52.20%
$14.86M
$2,060,158
5
-21.35%
$16.73M
$45,953
2
-2.16%
$17.7M
$31,190
2
-14.18%
$14.74M
$245,940
2
31.12%
$14.24M

HCWB Institutional Investors: Active Positions

Increased Positions4+16.67%2M+180.17%
Decreased Positions8-33.33%118,637-10.24%
New Positions4New2MNew
Sold Out Positions2Sold Out51,328Sold Out
Total Postitions20-16.67%3M+169.93%

HCWB Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Armistice Capital, Llc$769.004.5%2.02M+2MNew2024-12-31
Avantax Planning Partners, Inc.$106.000.62%279,54100%2024-12-31
Geode Capital Management, Llc$69.000.4%181,957-1,302-0.71%2024-12-31
Hightower Advisors, Llc$69.000.4%180,81000%2024-12-31
Cresset Asset Management, Llc$50.000.29%131,99000%2024-12-31
Pullen Investment Management, Llc$29.000.17%75,11600%2024-12-31
Blackrock, Inc.$16.000.1%42,989-1,359-3.06%2024-12-31
Vanguard Group Inc$14.000.08%37,67700%2024-12-31
Bridgeway Capital Management, Llc$13.000.08%34,700-50,000-59.03%2024-12-31
Xtx Topco Ltd$13.000.08%33,999+33,999New2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.